Table S5.
Combined responder analyses at end point for the RCT (ad hoc analyses; LOCF, full-analysis set)
| Definition of response | Response | Placebo (n=111) | GXR (n=114) | ATX (n=112) |
|---|---|---|---|---|
| ≥30% reduction from baseline in ADHD-RS-IV and CGI-I score of 1 or 2 | Number of participants | 111 | 112 | 112 |
| Responders, n (%) | 47 (42.3) | 72 (64.3) | 62 (55.4) | |
| Difference in % responders from placebo (95% CI; P-value) | 21.9 (9.2–34.7; P<0.001) | 13.0 (0–26.0; P=0.017) | ||
| ≥50% reduction from baseline in ADHD-RS-IV and CGI-I score of 1 or 2 | Number of participants | 111 | 112 | 112 |
| Responders, n (%) | 33 (29.7) | 60 (53.6) | 47 (42.0) | |
| Difference in % responders from placebo (95% CI; P-value) | 23.8 (11.3–36.4; P<0.001) | 12.2 (−0.2 to 24.7; P=0.018) |
Abbreviations: ADHD-RS-IV, Attention-Deficit/Hyperactivity Disorder Rating Scale version IV; ATX, atomoxetine; CGI-I, Clinical Global Impression – Improvement scale; CI, confidence interval; GXR, guanfacine extended release; LOCF, last observation carried forward; RCT, randomized controlled trial.